Note 18 - Subsequent Events	9 Months Ended
Sep. 30, 2025
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 19. SUBSEQUENT EVENTS The Company has evaluated all subsequent events through the filing date of this Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the condensed consolidated financial statements as of September 30, 2025, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. Except as described below, there were no subsequent events which required recognition, adjustment to, or disclosure in, the unaudited condensed consolidated financial statements. Submission of Matters to a Vote of Security Holders and Annual Meeting On October 16, 2025, the Company held its annual meeting of stockholders. Matters considered at that meeting are relevant to certain subsequent events outlined below. Additional details and information about other matters submitted to a vote of security holders and related results of the meeting can be found in the Company’s Current Report on Form 8-K filed on October 20, 2025. Increase in Shares Authorized Under 2017 Plan On October 16, 2025, stockholders approved an amendment to increase the shares authorized under the 2017 Plan by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock and to make corresponding changes to the share grant limitations in the 2017 Plan. Series E Preferred Stock Closing and Conversion to Common Stock The 2025 Preferred Stock Purchase Agreement dated as of August 19, 2025 between the Company and Mr. Lazar provided for the ability of Mr. Lazar to assign, transfer and/or sell his shares of Series D Preferred Stock, Series E Preferred Stock, the shares of Common Stock underlying the Transferred Stock (as defined below) and/or his right acquire such securities (see Note 8, “Financing Activities”). On October 9, 2025, Mr. Lazar tendered his resignation as Chief Executive Officer and a director of NovaBay and entered into a securities purchase agreement with R01 Fund LP (“R01”) and Framework Ventures IV L.P. (“Framework” and, together with R01, the “Purchasers”) to effect such transfer. Pursuant to the agreement, Mr. Lazar assigned to the Purchasers all of Mr. Lazar’s right, title and interest in (i) 441,326 outstanding shares of Series D Preferred Stock and (ii) the rights and obligations to purchase all 268,750 shares of Series E Preferred Stock (together with the Series D Preferred Stock, the “Transferred Stock” and the transactions contemplated by the Securities Purchase Agreement, the “Lazar Sale”), each of which were purchased from the Company by Mr. Lazar pursuant to the 2025 Preferred Stock Purchase Agreement. On October 16, 2025, pursuant to the 2025 Preferred Stock Purchase Agreement, the Company filed the certificate of designations relating to the Series E Preferred Stock and issued 268,750 shares to the Purchasers for gross proceeds of approximately $2.2 million (the “Series E Preferred Closing” and together with the Lazar Sale, the “2025 Preferred Stock Issuance”). Each share of Series E Preferred Stock was eligible to convert at the option of the holder or, otherwise, automatically convert 30 business days after the Stockholder Approval, into 160 shares of Common Stock, for an aggregate of 43,000,000 shares of Common Stock. On October 21, 2025, at the option of the Purchasers, all 268,750 shares of Series E Preferred Stock were converted into 43,000,000 shares of Common Stock. October 2025 Pre-Funded Warrants On October 16, 2025, the Company issued and sold pre-funded warrants (the “October 2025 Pre-Funded Warrants”) to purchase an aggregate of 5,405,406 shares of Common Stock, to R01 and Framework in two transactions for aggregate gross proceeds of approximately $6.0 million The purchase price was $1.10 per October 2025 Pre-Funded Warrant, representing 110% of the closing price of the Common Stock on the day before the issuance, less the $0.01 exercise price for each such October 2025 Pre-Funded Warrant. The October 2025 Pre-Funded Warrants are exercisable for shares of Common Stock at any time after January 1, 2026, subject to receipt of stockholder approval. NYSE Compliance On October 20, 2025, the Company was notified by NYSE American that the Company had regained compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide. Series D Preferred Stock Conversion to Common Stock On October 21, 2025, three business days after the Conversion Approval, the 481,250 shares of Series D Preferred Stock were automatically converted into 77,000,000 shares of Common Stock. Redemption of Series F Preferred Stock Subsequent to September 30, 2025, 639,933 shares of Series F Preferred Stock were redeemed for $175,000.

Note 18 - Subsequent Events

9 Months Ended

Sep. 30, 2025

NOTE 19. SUBSEQUENT EVENTS

The Company has evaluated all subsequent events through the filing date of this Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the condensed consolidated financial statements as of September 30, 2025, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. Except as described below, there were no subsequent events which required recognition, adjustment to, or disclosure in, the unaudited condensed consolidated financial statements.

Submission of Matters to a Vote of Security Holders and Annual Meeting

On October 16, 2025, the Company held its annual meeting of stockholders. Matters considered at that meeting are relevant to certain subsequent events outlined below. Additional details and information about other matters submitted to a vote of security holders and related results of the meeting can be found in the Company’s Current Report on Form 8-K filed on October 20, 2025.

Increase in Shares Authorized Under 2017 Plan

On October 16, 2025, stockholders approved an amendment to increase the shares authorized under the 2017 Plan by 1,000,000 shares of Common Stock resulting in a maximum number of shares currently available for issuance of 1,021,332 shares of Common Stock and to make corresponding changes to the share grant limitations in the 2017 Plan.

Series E Preferred Stock Closing and Conversion to Common Stock

The 2025 Preferred Stock Purchase Agreement dated as of August 19, 2025 between the Company and Mr. Lazar provided for the ability of Mr. Lazar to assign, transfer and/or sell his shares of Series D Preferred Stock, Series E Preferred Stock, the shares of Common Stock underlying the Transferred Stock (as defined below) and/or his right acquire such securities (see Note 8, “Financing Activities”). On October 9, 2025, Mr. Lazar tendered his resignation as Chief Executive Officer and a director of NovaBay and entered into a securities purchase agreement with R01 Fund LP (“R01”) and Framework Ventures IV L.P. (“Framework” and, together with R01, the “Purchasers”) to effect such transfer. Pursuant to the agreement, Mr. Lazar assigned to the Purchasers all of Mr. Lazar’s right, title and interest in (i) 441,326 outstanding shares of Series D Preferred Stock and (ii) the rights and obligations to purchase all 268,750 shares of Series E Preferred Stock (together with the Series D Preferred Stock, the “Transferred Stock” and the transactions contemplated by the Securities Purchase Agreement, the “Lazar Sale”), each of which were purchased from the Company by Mr. Lazar pursuant to the 2025 Preferred Stock Purchase Agreement. On October 16, 2025, pursuant to the 2025 Preferred Stock Purchase Agreement, the Company filed the certificate of designations relating to the Series E Preferred Stock and issued 268,750 shares to the Purchasers for gross proceeds of approximately $2.2 million (the “Series E Preferred Closing” and together with the Lazar Sale, the “2025 Preferred Stock Issuance”). Each share of Series E Preferred Stock was eligible to convert at the option of the holder or, otherwise, automatically convert 30 business days after the Stockholder Approval, into 160 shares of Common Stock, for an aggregate of 43,000,000 shares of Common Stock. On October 21, 2025, at the option of the Purchasers, all 268,750 shares of Series E Preferred Stock were converted into 43,000,000 shares of Common Stock.

October 2025 Pre-Funded Warrants

On October 16, 2025, the Company issued and sold pre-funded warrants (the “October 2025 Pre-Funded Warrants”) to purchase

an aggregate of 5,405,406 shares of Common Stock, to R01 and Framework in two transactions for aggregate gross proceeds of approximately $6.0 million The purchase price was $1.10 per October 2025 Pre-Funded Warrant, representing 110% of the closing price of the Common Stock on the day before the issuance, less the $0.01 exercise price for each such October 2025 Pre-Funded Warrant. The October 2025 Pre-Funded Warrants are exercisable for shares of Common Stock at any time after January 1, 2026, subject to receipt of stockholder approval.

NYSE Compliance

On October 20, 2025, the Company was notified by NYSE American that the Company had regained compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide.

Series D Preferred Stock Conversion to Common Stock

On October 21, 2025, three business days after the Conversion Approval, the 481,250 shares of Series D Preferred Stock were automatically converted into 77,000,000 shares of Common Stock.

Redemption of Series F Preferred Stock

Subsequent to September 30, 2025, 639,933 shares of Series F Preferred Stock were redeemed for $175,000.